Amgen’s Dmab Works in Cancer Trial

Xconomy Seattle — 

Amgen (NASDAQ: AMGN), the world’s largest biotechnology company, said today that its lead experimental drug, denosumab, reached all its goals in a clinical trial of more than 2,000 women with breast cancer. Women with breast cancer often have tumors spread to their bones, and the drug, “dmab,” was able to delay the time it took for that damaging effect to occur, when compared with Novartis’ zoledronic acid (Zometa). The Amgen drug, which is also vying for FDA approval as an osteoporosis treatment, has been studied for more than a decade as a cancer drug at Amgen’s Seattle research center, as I described in a feature in October.